Johnson & Johnson (NYSE:JNJ) Shares Sold by Baker Boyer National Bank

Baker Boyer National Bank trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% during the second quarter, HoldingsChannel reports. The fund owned 8,452 shares of the company’s stock after selling 323 shares during the quarter. Johnson & Johnson comprises 0.5% of Baker Boyer National Bank’s holdings, making the stock its 19th biggest position. Baker Boyer National Bank’s holdings in Johnson & Johnson were worth $1,399,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Peak Asset Management LLC boosted its holdings in Johnson & Johnson by 9.3% during the first quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after buying an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Johnson & Johnson by 0.9% during the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock worth $116,071,000 after buying an additional 6,836 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in Johnson & Johnson by 21.8% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock worth $140,050,000 after buying an additional 161,687 shares in the last quarter. Tekla Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 12.8% in the first quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after purchasing an additional 82,100 shares in the last quarter. Finally, Wisconsin Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 0.8% in the first quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after purchasing an additional 127 shares in the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.41 on Tuesday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The firm has a fifty day moving average of $166.21 and a 200-day moving average of $161.83. The firm has a market capitalization of $422.10 billion, a P/E ratio of 32.88, a PEG ratio of 3.26 and a beta of 0.54. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.59 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were paid a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Insider Activity

In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. Finally, Citigroup initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $170.65.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.